Observational studyBMC cardiovascular disorders2026
Predicting atrial fibrillation recurrence after radiofrequency ablation using the AIFV system: a prospective observational study.
Observational study in BMC cardiovascular disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary vein isolation (PVI) has become the cornerstone of atrial fibrillation (AF) treatment. Nevertheless, the efficacy of radiofrequency ablation remains limited by a substantial rate of recurrence. The selection of anesthesia, the surgeon's operative experience and medical expertise, as well as the ablation surgery strategy, all have an impact on the recurrence after atrial fibrillation surgery. Our research aims to explore a novel method for predicting atrial fibrillation (AF) recurrence.
methodsThis study enrolled 148 patients with atrial fibrillation (AF) undergoing first-time radiofrequency ablation. Based on the data from the AIFV system (an artificial intelligence-based ablation quality analysis system that generates structured Vistag scores from CARTO3 mapping data), patients were divided into two groups: the high-score group(Vistag analysis scores ≥ V5) and the low-score group(scores < V5). Baseline characteristics, intraoperative parameters, and AIFV system-related data were collected. Multivariate logistic regression analysis was performed to identify factors associated with atrial fibrillation (AF) recurrence.
resultsAmong the 148 enrolled patients, 84 were categorized into the high-score group and 64 into the low-score group. Patients in the low-score group had significantly higher Left Ventricular End-Diastolic Volume (LVEDV), Left Ventricular Ejection Fraction (LVEF), and Left Ventricular End-Systolic Volume (LVESV), as well as a higher prevalence of diabetes (29.5% vs. 9.5%, p = 0.002). During a minimum follow-up of 365 days, 11 patients (13.1%) in the high-score group experienced recurrence of atrial arrhythmia, compared to 19 patients (29.7%) in the low-score group. Kaplan-Meier analysis revealed a significantly higher atrial arrhythmia-free survival rate in the high-score group (log-rank test, P = 0.012). Multivariate logistic regression analysis revealed that being in the high-score group was an independent protective factor against AF recurrence (OR = 0.383, 95% CI 0.160-0.912, P = 0.030).
conclusionsThe AIFV system was used to evaluate six procedural parameters in each atrial fibrillation procedure, which could play a crucial role in predicting the recurrence of atrial fibrillation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.